EMA's response to the COVID-19 pandemic: Putting people's health first
Submitted by Anonymous (not verified) on 10 August 2023 - 12:56
EMA's response to the COVID-19 pandemic: Putting people's health first
Release notes - production release version 1.6.30 July 2023 - Veterinary Medicinal Products Regulation: Union Product Database
Submitted by Anonymous (not verified) on 10 August 2023 - 9:55
Release notes - production release version 1.6.30 July 2023 - Veterinary Medicinal Products Regulation: Union Product Database
Human medicines European public assessment report (EPAR): Ilumetri, tildrakizumab, Psoriasis, Date of authorisation: 17/09/2018, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 10 August 2023 - 9:20
Human medicines European public assessment report (EPAR): Ilumetri, tildrakizumab, Psoriasis, Date of authorisation: 17/09/2018, Revision: 10, Status: Authorised
Non-Clinical and New Approach Methodologies European Specialised Expert Community
Submitted by Anonymous (not verified) on 9 August 2023 - 16:35
Non-Clinical and New Approach Methodologies European Specialised Expert Community
Mandate, objective and rules of procedure for the Non-Clinical and New Approach Methodologies European Specialised Expert Community
Submitted by Anonymous (not verified) on 9 August 2023 - 16:35
Mandate, objective and rules of procedure for the Non-Clinical and New Approach Methodologies European Specialised Expert Community
Revocation of authorisation for sickle cell disease medicine Adakveo
Submitted by Anonymous (not verified) on 9 August 2023 - 14:28
Revocation of authorisation for sickle cell disease medicine Adakveo
Human medicines European public assessment report (EPAR): Lantus, insulin glargine, Diabetes Mellitus, Date of authorisation: 09/06/2000, Revision: 40, Status: Authorised
Submitted by Anonymous (not verified) on 9 August 2023 - 14:22
Human medicines European public assessment report (EPAR): Lantus, insulin glargine, Diabetes Mellitus, Date of authorisation: 09/06/2000, Revision: 40, Status: Authorised
Withdrawn application: Lagevrio, molnupiravir, Date of withdrawal: 21/06/2023, Initial authorisation
Submitted by Anonymous (not verified) on 9 August 2023 - 9:50
Withdrawn application: Lagevrio, molnupiravir, Date of withdrawal: 21/06/2023, Initial authorisation
Methotrexate supply shortage
Submitted by Anonymous (not verified) on 9 August 2023 - 9:22
Methotrexate supply shortage
Informed consent for paediatric clinical trials in Europe 2015
Submitted by Anonymous (not verified) on 9 August 2023 - 8:19
Informed consent for paediatric clinical trials in Europe 2015